ADHD medication shortages

There are supply disruptions affecting various strengths of medicines licensed for the treatment of attention deficit hyperactivity disorder (ADHD). This has been caused by a combination of manufacturing issues and an increased global demand.

Affected brands and strengths are listed on the Central Alerting System, however it should be noted that remaining products cannot support an excessive increase in demand.

Prescribers may wish to utilise our recent Medicines Value Bulletin regarding methylphenidate XL tablets to find pharmacologically suitable alternatives if the regular medication is not available at this time.


Transfer of prescribing from private provider to NHS GP – RDTC of prescribing from private provider to NHS GP – RDTC

Medicines in Practice is a series of evidence–based publications specifically designed to support stakeholder medicines optimisation services.

This publication aims to provide guidance on what NHS prescribers need to be aware of when they are asked by a private healthcare provider, and/or patient, to take on the regular prescribing of a medication for a patient, including medicines supplied under formal shared care agreements. Based on suggested best practice it discusses the principles which underpin the transfer of patients from private to NHS provision and highlights Shared Care specific, and ethical considerations.

Medicines in Practice: Considerations for Sustainable Inhaler Prescribing

Medicines in Practice is a series of evidence–based publications specifically designed to support stakeholder medicines optimisation services.

Inhalers account for approximately 3% of all NHS carbon emissions. Reducing the carbon impact from inhaler prescribing has been identified as a significant area of focus for delivering a net zero NHS. This document aims to outline strategies that can be considered to promote optimal respiratory care, while minimising the environmental impact from inhalers and consequences of suboptimal disease management.

A briefing for ICSs regarding NICE TA875: Semaglutide for managing obesity

In March 2023 NICE published TA875: Technology Appraisal guidance for semaglutide (Wegovy®) for managing overweight and obesity. The guidance recommends semaglutide as an option for weight management when prescribed by a specialist service alongside a reduced-calorie diet and increased physical activity in adults if they meet the criteria specified. This briefing aims to provide advice to prescribers on how the treatment can be accessed and which patient groups are eligible to receive Wegovy®. The document explains some of the limitations of the treatment and the evidence base, as described by NICE and may help to manage patient expectations.

Formulary Assessment Tool: Tacalcitol (Curatoderm) Lotion and Ointment

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.

The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.

The Formulary Assessment tool for tacalcitol (Curatoderm) can be found here.

Prescribing for Population Health: Problematic Polypharmacy: Prescribing Cascades Evidence Evaluation

Prescribing for Population Health (PPH) is an ongoing series that aims to support ICSs to improve the health of the populations they serve.

Problematic polypharmacy is a significant concern with overprescribing and occurs where the prescribing of multiple medicines is either inappropriate or where the intended benefit of the medication is not realised.

The publication aims to raise awareness of potential prescribing cascades and to highlight resources, tools, and strategies to help identify, prevent, and resolve inappropriate cascades.

Prescribing Bulletin: Budget impact of metformin 1g immediate release tablet prescribing

The purpose of this bulletin is to highlight the rapid increase in price of metformin 1g tablets over the last year, and to raise awareness of the difference in price of metformin 1g immediate release (IR) tablets compared with 500mg IR tablets. It considers the potential budget impact to primary care of prescribing metformin 1g IR tablets across the ICSs in the North East & Yorkshire region and Greater Manchester.

Formulary assessment tool: Morphine sulfate (Actimorph) orodispersible tablets

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.

The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.

The Formulary assessment tool for morphine sulfate orodispersible tablets (Actimorph) can be found here.

Strategic Insight: Polypharmacy and overprescribing: an overview

Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System leaders. Through the analysis of data and communication with key stakeholders across the ICS, interventions to be undertaken by the ICS are proposed to Integrated Care Boards or associated committees.

This report provides an update on key primary care prescribing trends in the North of England with respect to polypharmacy, in order to support primary care teams in identifying key groups who may benefit from a structured medicines review.

Formulary assessment tool: Trifarotene (Aklief)

Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies.

The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The purpose of the document is to support consistent decision making by formulary groups and APCs.

The Formulary assessment tool for trifarotene (Aklief) can be found here.